Skip to main content

Table 2 Incidence rates, hazard ratios and competing risk of active TB associated with Fluticasone/salmeterol relative to Budesonide/formoterol in patients with COPD in intent-to-treat and as treated analysis

From: Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids

Fluticasone/salmeterol cohort Budesonide/formoterol cohort Crude HR (95%CI) Adjustedb HR (95%CI) Competing risk
subHR (95%CI)
event Person-Year IRa event Person-Year IRa
ITT analysis
Before propensity score matching
 TB 358 38,123.37 0.94% 175 28,559.41 0.61% 1.50 (1.26–1.80) 1.41 (1.17–1.70) 1.45 (1.21–1.74)
After propensity score matching
 TB 247 27,392.73 0.90% 172 27,689.85 0.62% 1.34 (1.07–1.69) 1.45 (1.14–1.85) 1.44 (1.19–1.75)
As treated analysis
Before propensity score matching
 TB 126 14,256.75 0.88% 66 10,120.93 0.65% 1.32 (0.98–1.78) 1.28 (0.94–1.73) 1.27 (0.94–1.71)
After propensity score matching
 TB 85 9512.25 0.89% 66 9872.11 0.67% 1.23 (0.73–2.07) 1.38 (0.79–2.42) 1.31 (0.95–1.81)
  1. aIR Incidence rate
  2. bAdjusted for age, gender, propensity score